CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
The CRC RAScan provides a single-kit solution for detecting KRAS and NRAS genetic mutations that are highly relevant when considering administration of select EGFR inhibitor therapies associated with metastatic colorectal cancer.
The initial launch will be in Europe. Financial terms of the agreement were not disclosed.
Transgenomic, 402-452-5416
Pages: 1 2